IPP Bureau
Ozempic 2.0 mg approved in the US for the treatment of type 2 diabetes
By IPP Bureau - March 29, 2022
Ozempic is now approved in the US at 0.5 mg,1.0 mg and 2.0 mg doses for the treatment of type 2 diabetes in adults
Dupixent is a star in Sanofi’s immunology strategy
By IPP Bureau - March 29, 2022
Dupixent peak sales ambition raised to more than €13 billion
Dysval gets regulatory approval in Japan
By IPP Bureau - March 29, 2022
Tardive dyskinesia (TD) is a movement disorder that is characterized by uncontrollable, abnormal and repetitive movements of the face, torso and/or other body parts, which may be disruptive and negatively impact patients
USFDA clears IND application for an intranasal RSV vaccine
By IPP Bureau - March 29, 2022
The companies are now preparing to initiate a Phase 1 trial to assess the safety and immunogenicity of BLB-201 in healthy volunteers
Carestream Health India showcases two new products at IRIA
By IPP Bureau - March 29, 2022
As a partner with IRIA, the company had a significant booth presence on-ground during the conference.
Lawrence Berkeley lab offers trial kit for CRAGE Genome Engineering Tool
By IPP Bureau - March 29, 2022
Novel tool bypasses plasmid-based expression to increase stability and significantly reduce development time for a variety of synthetic biotechnology products
Alembic Pharma acquires 100% stake in Aleor Dermaceuticals
By IPP Bureau - March 29, 2022
The amalgamation will integrate business operations and provide impetus to the existing portfolio of Alembic
University of Glasgow’s research centre to be named Mazumdar-Shaw Advanced Research Centre
By IPP Bureau - March 29, 2022
John Shaw, who is a Glasgow University graduate, along with his wife Kiran Mazumdar-Shaw had gifted US $ 7.5 million to the university in July 2019
Qure.ai raises US $ 40 million from healthcare investors Novo Holdings and HealthQuad
By IPP Bureau - March 29, 2022
The funding will accelerate the AI-driven healthcare company's market expansion into the global market and support new product development
USFDA approves EUA for second booster dose of Moderna
By IPP Bureau - March 29, 2022
50 µg dose approved for all adults over 50 years of age and immunocompromised adults over 18 years of age
AbbVie to showcase neuroscience portfolio at AAN 2022 annual meeting
By IPP Bureau - March 29, 2022
AbbVie to present 30 abstracts demonstrating its leadership in neuroscience, including continued migraine treatment research across the spectrum of the disease, commitment to patients with advanced Parkinson's disease, and new studies in spasticity and cervical dystonia
Solvay partners with Mitsubishi Chemical to recycle end-of-life medical components
By IPP Bureau - March 29, 2022
New collaboration will help customers reach sustainability goals for high-performance Udel PSU polymers in demanding applications.
Govt signs agreement with Sapigen Biologix to develop two vaccines
By IPP Bureau - March 28, 2022
Under the agreement, Technology Development Board and Bharat Biotech have pledged the support of Rs.200 crore each to create a continuous corpus of Rs.400 crores for the project
Metropolis recognises medical students with scholarship grants and awards
By IPP Bureau - March 28, 2022
Launched in the year 2018, MedEngage Scholarship Program is aimed at nurturing and nourishing medical talent in India
Tarlige tablets approved in Japan for treatment of patients with neuropathic pain
By IPP Bureau - March 28, 2022
In May 2021, Daiichi Sankyo had submitted a supplemental new drug application (sNDA) for Tarlige tablets based on results from a phase 3 trial in patients with CNP
